\newlabel{fig:reconstruction}{{1}{1}{The four operators of the phylomemy reconstruction process: 1. terms indexation, 2. similarity measures, 3. fields detection, 4. inter-temporal matching\relax}{figure.caption.1}{}}
\@LN{32}{0}
\@LN{33}{0}
\@LN{34}{0}
\@LN{35}{0}
\@LN{36}{0}
\@LN{37}{0}
...
...
@@ -83,14 +83,14 @@
\@LN{49}{0}
\@LN{50}{0}
\@LN{51}{0}
\@LN{52}{0}
\@LN{53}{0}
\@LN{54}{0}
\@LN{55}{0}
\citation{lobbe_exploring_2021}
\@writefile{lof}{\contentsline{figure}{\numberline{2}{\ignorespaces Phylomemy of 1794 COVID-19 vaccines trials recorded between February 2020 and October 2021 in the COVID-NMA database. Online and interactive version available at \href{http://maps.gargantext.org/unpublished_phylo/vaccines_publications_10_2021/}{maps.gargantext.org/publications}\relax}}{2}{figure.caption.2}\protected@file@percent }
\newlabel{fig:phylomemy-randomized-unrandomized}{{2}{2}{Phylomemy of 1794 COVID-19 vaccines trials recorded between February 2020 and October 2021 in the COVID-NMA database. Online and interactive version available at \href{http://maps.gargantext.org/unpublished_phylo/vaccines_publications_10_2021/}{maps.gargantext.org/publications}\relax}{figure.caption.2}{}}
\@LN@col{1}
\@LN{52}{1}
\@LN{53}{1}
\@LN{54}{1}
\@LN{55}{1}
\@LN{56}{1}
\@LN{57}{1}
\@LN{58}{1}
...
...
@@ -114,11 +114,11 @@
\@LN{76}{1}
\@LN{77}{1}
\@LN{78}{1}
\@LN@col{2}
\@LN{79}{1}
\@LN{80}{1}
\@LN{81}{1}
\@LN{82}{1}
\@LN@col{2}
\@LN{83}{1}
\@LN{84}{1}
\@LN{85}{1}
...
...
@@ -145,16 +145,16 @@
\@LN{106}{1}
\@LN{107}{1}
\@LN{108}{1}
\@LN{109}{1}
\@LN{110}{1}
\@LN{111}{1}
\@LN{112}{1}
\citation{chumakove_old_2021}
\citation{chumakove_old_2021}
\citation{krause_considerations_2021}
\@writefile{lof}{\contentsline{figure}{\numberline{3}{\ignorespaces A focus of \autoref{fig:phylomemy-randomized-unrandomized}. In red are highlighted all the trials evaluating heterologous primary vaccination and heterologous booster. We circle the heterologous trials involving different platforms.\relax}}{3}{figure.caption.3}\protected@file@percent }
\newlabel{fig:heterologous}{{3}{3}{A focus of \autoref{fig:phylomemy-randomized-unrandomized}. In red are highlighted all the trials evaluating heterologous primary vaccination and heterologous booster. We circle the heterologous trials involving different platforms.\relax}{figure.caption.3}{}}
\@LN@col{1}
\@LN{109}{2}
\@LN{110}{2}
\@LN{111}{2}
\@LN{112}{2}
\@LN{113}{2}
\@LN{114}{2}
\@LN{115}{2}
...
...
@@ -187,11 +187,11 @@
\@LN{142}{2}
\@LN{143}{2}
\@LN{144}{2}
\@LN@col{2}
\@LN{145}{2}
\@LN{146}{2}
\@LN{147}{2}
\@LN{148}{2}
\@LN@col{2}
\@LN{149}{2}
\@LN{150}{2}
\@LN{151}{2}
...
...
@@ -224,6 +224,10 @@
\@LN{178}{2}
\@LN{179}{2}
\@LN{180}{2}
\@LN{181}{2}
\@LN{182}{2}
\@LN{183}{2}
\@LN{184}{2}
\citation{boutron_nma_2020,nguyen_research_2021}
\citation{delanoe_mining_2021}
\bibdata{references}
...
...
@@ -239,10 +243,6 @@
\@writefile{lof}{\contentsline{figure}{\numberline{4}{\ignorespaces Phylomemy of the randomized only COVID-19 vaccines trials. In blue, we highlight all the trials with an associated publication (i.e., preprint or peer-reviewed articles).\relax}}{4}{figure.caption.4}\protected@file@percent }
\newlabel{fig:phylomemy-randomized-publications}{{4}{4}{Phylomemy of the randomized only COVID-19 vaccines trials. In blue, we highlight all the trials with an associated publication (i.e., preprint or peer-reviewed articles).\relax}{figure.caption.4}{}}
% If your first paragraph (i.e. with the \dropcap) contains a list environment (quote, quotation, theorem, definition, enumerate, itemize...), the line after the list may have some extra indentation. If this is the case, add \parshape=0 to the end of the list environment.
\dropcap{O}ver the past two years, the ongoing COVID-19 pandemic has impacted a wide number of human domains: from economy to education, from public health to politics, etc. Among others, Science swung early on into action to find both a cure and an effective vaccine. This resulted in an unprecedented flow of publications, articles and reports whose very textual contents convey thematic and temporal information of their own. In order to make sense of this growing constellation of scientific documents, our report aims at reconstructing and visualizing their collective structure and semantic dynamics. In particular, we will monitor the evolution of COVID-19 vaccines trials from the \textit{COVID-NMA database}\footnote{The COVID-NMA database contains all trials assessing vaccines for COVID-19 registered on the International Clinical Trials Registry Platform (ICTRP), Clinicaltrials.gov and the EU clinical trials registry.}~\cite{boutron_nma_2020,nguyen_research_2021} by applying the \textit{phylomemy reconstruction process}~\cite{delanoe_mining_2021}. We will then combine the expertise of epidemiologists and \textit{complex systems} researchers to interpret the resulting visualizations and reveal insights for upcoming COVID-19 research.
For the purpose of this study, the COVID-NMA database has been reduced to a pruned corpus called~$\mathcal{D}_{vt}$ (see \hyperref[pre-processing]{Materials}).
\dropcap{O}ver the past two years, the ongoing COVID-19 pandemic has impacted a wide number of human domains: from economy to education, from public health to politics, etc. Among others, Science swung early on into action to find both a cure and an effective vaccine. This resulted in an unprecedented flow of publications, articles and trials reports whose very textual contents convey thematic and temporal information of their own. In order to make sense of this growing constellation of scientific documents, our contribution aims at reconstructing and visualizing their collective structure and semantic dynamics. In particular, \textbf{we will monitor the evolution of COVID-19 vaccines trials descriptions} from the \textit{COVID-NMA database} by applying the \textit{phylomemy reconstruction process}~\cite{delanoe_mining_2021}: an innovative approach from the field of \textit{Complex Systems}~\cite{chavalarias_draw_2021}. The COVID-NMA database stores the curated dataset of all the clinial trials available in the set of international primary and secondary trial registries\footnote{All trials registered on the International Clinical Trials Registry Platform (ICTRP), Clinicaltrials.gov and the EU clinical trials registry}~\cite{boutron_nma_2020,nguyen_research_2021} (see \hyperref[pre-processing]{Materials}). For the purpose of this study, the COVID-NMA database has been reduced to a pruned corpus called~$\mathcal{D}_{vt}$. We will then combine the expertise of epidemiologists and \textit{complex systems} researchers to interpret the resulting visualizations and reveal insights for upcoming COVID-19 research.
